[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507258":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":38,"centralContacts":43,"locations":48,"responsibleParty":68,"collaborators":72,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":89,"studyType":90,"phases":10,"briefSummary":91,"conditions":92,"keywords":99,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Universitätsklinik fur Frauenheilkunde, Inselspital Bern","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer female participants",null,"Fertility status before and after gonadotoxic treatment",[13,14,15],"Diagnostic Test: Blood samples for analysis","Other: Satisfaction evaluation","Other: Quality of Life questionnaire",{"label":17,"type":10,"description":11,"interventionNames":18},"Cancer male participants",[13,19,14,15],"Diagnostic Test: Sperm samples for analysis",[21,26,30,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","Blood samples for analysis","Test hormone levels in blood",[9,17],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Sperm samples for analysis","Spermiogram",[17],{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"Satisfaction evaluation","Participant satisfaction assessment",[9,17],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Quality of Life questionnaire","The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)",[9,17],[39],{"name":40,"affiliation":41,"role":42},"Michael von Wolff, Prof. Dr.","Insel Gruppe AG, University Hospital Bern","PRINCIPAL_INVESTIGATOR",[44],{"name":40,"role":45,"phone":46,"phoneExt":10,"email":47},"CONTACT","0041316321301","michael.vonwolff@insel.ch",[49],{"facility":50,"status":51,"city":52,"state":10,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"University Women's Hospital (Inselspital)","RECRUITING","Bern","3010","Switzerland","CH",{"type":57,"coordinates":58},"Point",[59,60],7.44744,46.94809,{"lat":60,"lon":59},[63,65],{"name":40,"role":45,"phone":64,"phoneExt":10,"email":47},"+ 41 31 632 13 01",{"name":66,"role":45,"phone":10,"phoneExt":10,"email":67},"Irene Marcu, PhD","irene.marcu@insel.ch",{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Michael von Wolff","Prof. Dr. med. Michael von Wolff",[73],{"name":74,"class":6},"University of Bern","100507258","impact-of-gonadotoxic-therapies-on-fertility-100507258",false,"NCT05885048","Impact of Gonadotoxic Therapies on Fertility","FertiTOX - Platform for Fertility Related Gonadotoxicity of Cancer Therapies","FertiTOX","Inclusion Criteria:\n\n* Patients with cancer or with benign reasons undergoing chemotherapy and\u002For radiotherapy of the pelvis (females) and the testicles (males) and\u002For immune therapy;\n* Willing to participate;\n* Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);\n* Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).\n\nExclusion Criteria:\n\n* Missing consent;\n* Language barrier.","ALL","14 Years","50 Years",{"count":87,"type":88},7000,"ESTIMATED","10 Years","OBSERVATIONAL","The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer.\n\nThe main questions it aims to answer are:\n\n* in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve);\n* in males, if cancer therapies reduce sperm concentration (sperm quality).",[93,94,95,96,97,98],"Cancer","Fertility Issues","Fertility Preservation","Toxicity Due to Chemotherapy","Toxicity Due to Radiotherapy","Effects of Immunotherapy",[100],"Gonadotoxicity","2024-05-31",{"date":103,"type":104},"2024-06-03","ACTUAL",{"date":106,"type":104},"2023-12-01",{"date":108,"type":88},"2038-12-31",{"name":70,"class":6},1]